Page 17 - Access Pathway News Today

Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma News provided by Share this article Share this article PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced toda...

  Those looking to enter the healthcare field can begin their journey through a variety of programs at Nicola Valley Institute of Technology (NVIT), BC’s premier indigenous post-secondary institute. “We have three programs running,” explained Ivy McRae, HCA Program Coordinator. “We have the Access to Practical Nursing which is a bridging program into Practical Nursing; we have a healthcare aide program we are offering in the fall, and right now we have the HCAP program, which is the He...

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results News provided by Share this article Share this article PRINCETON, N.J., May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021. ...

NICE steps into the future 20th April 2021 Healthcare has changed dramatically since the National Institute of Health and Care Excellence (NICE) was established 22 years ago. We’ve seen incredible advancements in treatments for patients in all disease areas, from cancer and heart disease to genetic conditions, and the UK’s world-renowned life sciences sector continues to provide scientific breakthroughs that improve our understanding of diseases and how best to treat them. It’s against th...

Mothers heartbreaking four-year fight to get "too bright" daughter support for autism Kathryn Jacobs has done whatever she can to help her daughter - but its still not enough to get her an assessment 06:00, 21 JAN 2021 Updated The video will auto-play soon8Cancel Play now Sign up to the Grimsby Live newsletter for daily updates and breaking newsInvalid EmailSomething went wrong, please try again later. Sign up here! When you subscribe we will use the information you provide to send you these ne...

Date Time MHRA Innovative Licensing and Access Pathway is open for business The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the MHRA for a new era in medicines approvals in the UK. Central to realising this ambition is how the ILAP provides a single inte...

The MHRA Innovative Licensing and Access Pathway is open for business The Medicines and Healthcare products Regulatory Agency (MHRA) today, 1 January 2021, formally starts the Innovative Licensing and Access Pathway (ILAP). From: 1 January 2021 The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with i...

Apply for a licence to market a medicine in the UK How to license a medicine for sale in the UK, including applications through national and international routes. From: Contents Print this page This guidance also covers licensing a medicine in Northern Ireland through the centralised, decentralised and mutual recognition European procedures. Which procedure to follow There are several routes to obtain a marketing authorisation in the United Kingdom (UK), Great Britain (England, Scotla...

Source: UK Government The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the MHRA for a new era in medicines approvals in the UK. Central to realising this ambition is how the ILAP provides a single integrated platform for sustained collaborative working be...

Innovative Licensing and Access Pathway (ILAP) for medicines Guidance for applicants on applying to the ILAP From: Details The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications and repurposed medicines. The ILAP awards a new “innovative medicine” designation (Innovation Passport), utilises tools from a toolkit and a “Road Ma...